BSX
Boston Scientific Corp
Boston Scientific Corp historical holders
total: 9
Causeway Capital Management Boston Scientific Corp transactions over time
- Total transactions:
- 1
- New positions:
- 1
- Held since:
- 2026 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2026 Q2
Sarah Ketterer has been an institutional investor in Boston Scientific Corp (BSX) since 2026 Q2. According to 2026 Q2 report, Sarah Ketterer holds 720,339 shares with a market value of roughly $30.74M representing 0.33% of their equity portfolio. The fund/company first acquired BSX in 2026 Q2, initially purchasing 720,339 shares.
Does Sarah Ketterer still hold BSX?
Yes, Sarah Ketterer continues to hold Boston Scientific Corp (BSX). According to their 2026 Q2 report, they maintain a position of 720,339 shares valued at approximately $30.74M, representing 0.33% of their equity portfolio.
When did Sarah Ketterer first invest in BSX?
Sarah Ketterer first invested in Boston Scientific Corp (BSX) in 2026 Q2 at the reported quarter-end price of $42.68 per share, acquiring 720,339 shares in their initial purchase.
What is Sarah Ketterer's average cost basis for BSX?
Based on historical transaction data, Sarah Ketterer's estimated cost basis for Boston Scientific Corp (BSX) is approximately $42.68 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $42.68
BSX transactions history by Causeway Capital Management
1 result
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.33%
|
720,339
|
$42.68
|
$30,744,061
|
new
|
+0.33%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.